|
Page 1 of 4
The Directors of Probiomics Ltd welcome you to explore the Company's website which will inform you of our exciting opportunities for commercialisation and further research for our probiotic technology.
Probiotics represent a growing market, and Probiomics Ltd is well positioned in this area, with a proprietary strain which is demonstrated to be clinically effective in a range of disorders, a number of products currently in the market, new products under development and a sophisticated novel molecule discovery program based on our proprietary probiotic, PCC®.
For investment advice contact stockbrokers:
Taylor Collison Ltd - Sydney, David Whiting (02) 9232 1688
DJ Carmichael Pty Limited - Perth, Gerard Connolly (08) 9263 5265
Bell Potter - Perth, Geoff Sansom (08) 9326 7666
Disclaimer
The information in this website is intended to be useful and informative for customers of and investors in Probiomics Ltd. Whilst we take reasonable steps to ensure the content on this website created by us is correct at the time it is created, we give no warranty or representation as to the website’s security or as to the content’s integrity or accuracy or completeness.
Please also note that the contents of this website do not constitute an invitation or inducement to invest in shares of Probiomics Ltd or otherwise to engage in investment activity.
|
